
Achieve Life Sciences Inc
ACHV · NASDAQ · Healthcare / Biotechnology
6.32USD+0.03 (+0.48%)
Price History
Full chartMarket Stats
Previous Close6.29
Open6.30
Day Range5.93 – 6.43
52-Week Range2.62 – 8.64
Volume775.87K
Market Cap805.73M
P/E (TTM)0.00
Forward P/E35.34
EPS-1.66
Dividend Yield0.00%
Beta2.25
50-Day Avg7.27
200-Day Avg5.35
About
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Company Details
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Andrew D. Goldberg M.D.
- Employees28
- Headquarters22722 29th Dr. SE, Bothell, WA, United States, 98021, USA
- Websitehttps://www.achievelifesciences.com
Leadership
- Mr. Erik AtkissonChief Legal Officer · b. 1972
- Dr. Andrew D. Goldberg M.D.CEO, President & Director · b. 1982
- Mr. Mark K. Oki CPAChief Financial Officer · b. 1969
- Mr. Jerry WanVP of Finance & Principal Accounting Officer · b. 1982
- Dr. Mark L. Rubinstein M.D.Chief Medical Officer · b. 1968
- Mr. Mark ZappiaSenior Vice President of Commercial
- Mr. Ronald DadinoSenior Vice President of Chemistry, Manufacturing & Controls and Supply Chain
- Ms. Gloria CosgroveSenior Vice President of Global Quality
- Ms. Nicole P. JonesVice President of Strategic Communications & Stakeholder Relations
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Market Cap805.73M
Enterprise Value663.21M
Trailing P/E0.00
Forward P/E35.34
PEG Ratio17.68
Price / Sales5.09
Price / Book64.03
EPS-1.66
Book Value-0.143
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-58.05M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-844.99%
Return on Assets-29.21%
Shares Outstanding102.90M
Shares Float74.69M
Beta2.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%
Analyst Ratings
Strong Buy
Based on 8 analystsTarget 13.83
- Strong Buy7
- Buy1
Ownership Breakdown
- Institutions
- 82.06%
- Insiders
- 0.91%
- Retail / Other
- 17.03%
Top Institutional Holders
- venBio Partners LLC5.91M5.75%
- Logos Global Management LP5.42M5.27%
- Paradigm Biocapital Advisors LP4.95M4.81%
- Franklin Templeton Inc4.37M4.25%
- Propel Bio Management LLC4.03M3.92%
- Vivo Capital, LLC2.75M2.67%
- Eventide Asset Management, LLC2.22M2.16%
- Vanguard Capital Management, LLC2.20M2.14%
- Simplify Asset Management Inc.1.43M1.39%
- Wellington Management Company LLP1.43M1.39%
- Marshall Wace Asset Management Ltd1.02M0.99%
- Spruce Street Capital LP736.64K0.72%
Top Fund Holders
- Vanguard MStar Total Stk Mkt Idx Invest3.11M3.02%
- Eventide Healthcare & Life Sciences I2.22M2.16%
- iShares Russell 2000 ETF1.96M1.91%
- Franklin Biotechnology Discv A(acc)USD1.93M1.88%
- Simplify Propel Opportunities ETF1.43M1.39%
- State Street® SPDR® S&P® Biotech ETF1.42M1.38%
- Franklin Biotechnology Discovery A1.10M1.06%
- Fidelity Small Cap Index844.53K0.82%
Stock Splits
- Jul 31, 20201:20
- May 24, 20181:10
- Aug 3, 20171:11
- Aug 21, 20081:18